167PUtilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER). (13th May 2019) - Mougalian, S; Wang, E; Alexis, K; Feinberg, B A; Nero, D; Miller, T; Laney, J; Chatterjee, D; Knoth, R; Kish, J